Navigation Links
SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients

CARLSBAD, Calif., July 20 /PRNewswire/ -- SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, recently introduced a new advanced lens design for keratoconus patients. ClearKone(TM) is a revolutionary contact lens that takes advantage of the best features of the hybrid platform, providing superior visual acuity, centration, stability, and all-day comfort. The patent-pending design is optimized to vault the predominant irregularities of the keratoconic cornea, thus effectively restoring vision to a vast majority of irregular cornea patients, without compromising comfort or eye health, even in the most challenging cases. ClearKone(TM) is now available in limited release in the United States, Canada and Puerto Rico.

SynergEyes lenses are the only FDA-cleared hybrid contact lenses specifically designed for keratoconus vision correction. The SynergEyes(R) KC lens was introduced in 2006, and many keratoconus patients are successfully wearing this design. However, SynergEyes(R) KC is most successful on central, nipple cones, which represent only a portion of the total number of keratoconus cases.

"SynergEyes recognized the need to develop a hybrid contact lens design that could fit a much broader spectrum of keratoconus patients, including oval cones, highly advanced central cones, decentered cones and depending on the specifics of the case, globus keratoconus and pellucid marginal degeneration," says Kellie Kaseburg, Vice President of Global Marketing for SynergEyes. "The ClearKone(TM) lens does just that and will allow many more keratoconus patients to experience the benefits of hybrid technology."

The ClearKone(TM) lens utilizes revolutionary hybrid technology to give keratoconus patients the very best technology has to offer -- the excellent visual clarity of a high-oxygen rigid gas permeable contact lens and the all-day comfort and convenience of a soft lens. What makes the ClearKone(TM) lens different from other SynergEyes lenses is the design of the lens itself and the technique used to fit it.

"The ClearKone(TM) hybrid contact lens gives keratoconus patients wearing RGP lenses or a piggyback system a new way to have clearer, more stable vision and better comfort," says Dr. Morris Sheffer of Charlotte, North Carolina. "The design of ClearKone(TM) enables the lens to center very well on irregularly shaped corneas, to provide crisper vision than any other contact lens we have tried. Since the lens is designed to 'vault' over the peak of the cornea, the comfort is also greatly improved. Our patients love the improvement in comfort and vision they get with ClearKone(TM)!"

ClearKone(TM) is currently being prescribed in a limited number of locations in the United States, Canada and Puerto Rico. Keratoconus patients can visit to locate a ClearKone(TM) practitioner.

Incorporating patented HyperBond(TM) technology and HydrolEyes(TM) surface science, the SynergEyes(R) contact lenses with FDA market clearance include: SynergEyes(R) A for naturally occurring ametropia, targeting patients with astigmatism, current gas permeable lens wearers, and patients demanding optimized vision; the SynergEyes(R) Multifocal lens for presbyopia; SynergEyes(R) KC and ClearKone(TM) for keratoconus; and the SynergEyes(R) PS for post-surgery and post-trauma refractive errors.


    Kellie Kaseburg
    Vice President, Global Marketing

This release was issued through eReleases(TM). For more information, visit

SOURCE SynergEyes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s ... America Annual Meeting from November 29 to December 4, 2015. , MED-TAB ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology: